Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient.
Fiche du document
31 décembre 2023
- doi: 10.1080/15384047.2023.2193116
- issn: 1538-4047
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1080/15384047.2023.2193116
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/36967525
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1555-8576
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_365141E36CC98
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
TherapyCiter ce document
S. Anchisi et al., « Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient. », Serveur académique Lausannois, ID : 10.1080/15384047.2023.2193116
Métriques
Partage / Export
Résumé
The treatment of BRAFV600E mutant melanoma has been revolutionized by BRAF inhibitors. Furthermore, the BRAF/MEK combination has shown further improvement in clinical outcomes in advanced and in adjuvant melanoma patients. In low-grade ovarian tumors, BRAF inhibitor use has been also proposed. Here we present a patient with an excellent, lasting response to BRAF therapy alone. At first progression, after more than two years on BRAF monotherapy, we could not identify any molecular mechanisms explaining resistance. After a switch to dual BRAF/MEK therapy, the patient responded. However, despite the initial response clinical the patient again progressed, this time with the appearance of a KRAS G12C mutation, which could not be overcome by BRAF/MEK therapy. We provide evidence that BRAF inhibitor alone can be highly beneficial in BRAF mutant low-grade ovarian tumors and the resistance mechanisms are similar to that of other BRAF mutant tumors, including in melanoma.